Samsung Biologics Co.,Ltd. (207940.KS)

KRW 959000.0

(-2.14%)

Gross Profit Summary of Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.'s latest annual gross profit in 2023 was 1802.76 Billion KRW , up 22.77% from previous year.
Samsung Biologics Co.,Ltd.'s latest quarterly gross profit in 2024 Q3 was 1187.07 Billion KRW , down -16.0% from previous quarter.
Samsung Biologics Co.,Ltd. reported a annual gross profit of 1468.44 Billion KRW in annual gross profit 2022, up 102.14% from previous year.
Samsung Biologics Co.,Ltd. reported a annual gross profit of 726.45 Billion KRW in annual gross profit 2021, up 74.6% from previous year.
Samsung Biologics Co.,Ltd. reported a quarterly gross profit of 1187.07 Billion KRW for 2024 Q3, down -16.0% from previous quarter.
Samsung Biologics Co.,Ltd. reported a quarterly gross profit of 410.46 Billion KRW for 2024 Q1, down -22.74% from previous quarter.

Annual Gross Profit Chart of Samsung Biologics Co.,Ltd. (2023 - 2014)

Historical Annual Gross Profit of Samsung Biologics Co.,Ltd. (2023 - 2014)

Year	Gross Profit	Gross Profit Growth
2023	1802.76 Billion KRW	22.77%
2022	1468.44 Billion KRW	102.14%
2021	726.45 Billion KRW	74.6%
2020	416.07 Billion KRW	116.7%
2019	192 Billion KRW	32.27%
2018	145.15 Billion KRW	10.14%
2017	131.8 Billion KRW	396.73%
2016	26.53 Billion KRW	212.88%
2015	-23.5 Billion KRW	-19.2%
2014	-19.71 Billion KRW	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	647.74 Billion KRW	57.81%
2024 Q3	1187.07 Billion KRW	-16.0%
2024 Q1	410.46 Billion KRW	-22.74%
2023 Q1	342.54 Billion KRW	-26.22%
2023 Q3	501.81 Billion KRW	17.48%
2023 Q2	427.14 Billion KRW	24.7%
2023 Q4	531.26 Billion KRW	5.87%
2023 FY	1802.76 Billion KRW	22.77%
2022 Q2	288.24 Billion KRW	25.47%
2022 FY	1468.44 Billion KRW	102.14%
2022 Q4	464.29 Billion KRW	-4.5%
2022 Q3	486.17 Billion KRW	68.67%
2022 Q1	229.72 Billion KRW	19.05%
2021 Q2	211.39 Billion KRW	96.92%
2021 FY	726.45 Billion KRW	74.6%
2021 Q4	192.97 Billion KRW	-10.14%
2021 Q3	214.74 Billion KRW	1.59%
2021 Q1	107.34 Billion KRW	-21.22%
2020 Q4	136.26 Billion KRW	57.17%
2020 Q3	86.69 Billion KRW	-18.24%
2020 Q1	87.06 Billion KRW	-34.08%
2020 FY	416.07 Billion KRW	116.7%
2020 Q2	106.04 Billion KRW	21.8%
2019 Q1	-394.33 Million KRW	-100.91%
2019 FY	192 Billion KRW	32.27%
2019 Q4	132.08 Billion KRW	170.66%
2019 Q3	48.8 Billion KRW	323.79%
2019 Q2	11.51 Billion KRW	3020.18%
2018 Q2	43 Billion KRW	70.44%
2018 FY	145.15 Billion KRW	10.14%
2018 Q4	43.21 Billion KRW	28.19%
2018 Q3	33.71 Billion KRW	-21.6%
2018 Q1	25.22 Billion KRW	-64.25%
2017 Q4	70.56 Billion KRW	89.99%
2017 Q1	17.7 Billion KRW	5.84%
2017 FY	131.8 Billion KRW	396.73%
2017 Q2	6.38 Billion KRW	-63.92%
2017 Q3	37.14 Billion KRW	481.37%
2016 Q3	1.98 Billion KRW	-80.29%
2016 Q2	10.06 Billion KRW	548.69%
2016 Q4	16.72 Billion KRW	743.48%
2016 Q1	-2.24 Billion KRW	0.0%
2016 FY	26.53 Billion KRW	212.88%
2015 FY	-23.5 Billion KRW	-19.2%
2014 FY	-19.71 Billion KRW	0.0%

Peer Gross Profit Comparison of Samsung Biologics Co.,Ltd.

Name	Gross Profit	Gross Profit Difference
ORIENT BIO Inc.	9.58 Billion KRW	-18709.357%
Green Cross Holdings Corporation	603.58 Billion KRW	-198.677%
Green Cross Holdings Corporation	458.68 Billion KRW	-293.026%
Pharmicell Co., Ltd.	14.95 Billion KRW	-11954.443%
Green Cross Corporation	458.68 Billion KRW	-293.026%
GeneOne Life Science, Inc.	-14.98 Billion KRW	12131.017%
Celltrion, Inc.	1010.9 Billion KRW	-78.332%
SK bioscience Co.,Ltd.	142.24 Billion KRW	-1167.385%
SK Biopharmaceuticals Co., Ltd.	308.37 Billion KRW	-484.602%
Prestige BioPharma Limited	689.07 Million KRW	-261520.95%